
End Stage Renal Disease Market by Treatment (Dialysis, Transplantation), Diagnosis (Blood Tests, Imaging Tests, Kidney Sample Removal For Testing), End-User - Global Forecast 2024-2030
Description
End Stage Renal Disease Market by Treatment (Dialysis, Transplantation), Diagnosis (Blood Tests, Imaging Tests, Kidney Sample Removal For Testing), End-User - Global Forecast 2024-2030
The End Stage Renal Disease Market size was estimated at USD 46.29 billion in 2023 and expected to reach USD 53.09 billion in 2024, at a CAGR 14.80% to reach USD 121.65 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the End Stage Renal Disease Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the End Stage Renal Disease Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the End Stage Renal Disease Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Asahi Kasei Medical Co., Ltd., AstraZeneca, B. Braun SE, Baxter International, Inc., Becton, Dickinson and Company, Bristol-Myers Squibb Company, Davita Healthcare Partners Inc., Fresenius Medical Care AG & Co. KGaA, GlaxoSmithKline PLC, Kissei Pharmaceutical Co., Ltd, Medtronic PLC, Nikkiso Co., Ltd., Pfizer Inc., and Sanofi SA.
Market Segmentation & Coverage
This research report categorizes the End Stage Renal Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:
Treatment
Dialysis
Hemodialysis
Peritoneal Dialysis
Wearable Artificial Kidney
Transplantation
Diagnosis
Blood Tests
Imaging Tests
Kidney Sample Removal For Testing
Urine Tests
End-User
Dialysis Centres
Hospital & Clinics
Research & Academic Institutes
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the End Stage Renal Disease Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the End Stage Renal Disease Market?
3. What are the technology trends and regulatory frameworks in the End Stage Renal Disease Market?
4. What is the market share of the leading vendors in the End Stage Renal Disease Market?
5. Which modes and strategic moves are suitable for entering the End Stage Renal Disease Market?PDF E-mail From Publisher (2-5)Users License
Table of Contents
186 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. End Stage Renal Disease Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Proliferation in number of people suffering from chronic kidney disease
- 5.1.1.2. Growing geriatric population with hypertension and diabetes
- 5.1.1.3. Increasing lifestyle changes and consumption of processed food
- 5.1.2. Restraints
- 5.1.2.1. Risk of complications
- 5.1.3. Opportunities
- 5.1.3.1. Introduction of new technologically enhanced products
- 5.1.3.2. Increasing investment in research and development activities coupled with collaborations among manufacturers
- 5.1.4. Challenges
- 5.1.4.1. Stringent regulatory protocols for the approval of new devices
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. End Stage Renal Disease Market, by Treatment
- 6.1. Introduction
- 6.2. Dialysis
- 6.3.1. Hemodialysis
- 6.3.2. Peritoneal Dialysis
- 6.3.3. Wearable Artificial Kidney
- 6.3. Transplantation
- 7. End Stage Renal Disease Market, by Diagnosis
- 7.1. Introduction
- 7.2. Blood Tests
- 7.3. Imaging Tests
- 7.4. Kidney Sample Removal For Testing
- 7.5. Urine Tests
- 8. End Stage Renal Disease Market, by End-User
- 8.1. Introduction
- 8.2. Dialysis Centres
- 8.3. Hospital & Clinics
- 8.4. Research & Academic Institutes
- 9. Americas End Stage Renal Disease Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific End Stage Renal Disease Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa End Stage Renal Disease Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Amgen Inc.
- 13.1.2. Asahi Kasei Medical Co., Ltd.
- 13.1.3. AstraZeneca
- 13.1.4. B. Braun SE
- 13.1.5. Baxter International, Inc.
- 13.1.6. Becton, Dickinson and Company
- 13.1.7. Bristol-Myers Squibb Company
- 13.1.8. Davita Healthcare Partners Inc.
- 13.1.9. Fresenius Medical Care AG & Co. KGaA
- 13.1.10. GlaxoSmithKline PLC
- 13.1.11. Kissei Pharmaceutical Co., Ltd
- 13.1.12. Medtronic PLC
- 13.1.13. Nikkiso Co., Ltd.
- 13.1.14. Pfizer Inc.
- 13.1.15. Sanofi SA
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. END STAGE RENAL DISEASE MARKET RESEARCH PROCESS
- FIGURE 2. END STAGE RENAL DISEASE MARKET SIZE, 2023 VS 2030
- FIGURE 3. END STAGE RENAL DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. END STAGE RENAL DISEASE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. END STAGE RENAL DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. END STAGE RENAL DISEASE MARKET DYNAMICS
- FIGURE 7. END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
- FIGURE 8. END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
- FIGURE 10. END STAGE RENAL DISEASE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 12. END STAGE RENAL DISEASE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. END STAGE RENAL DISEASE MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. END STAGE RENAL DISEASE MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.